By studying the effects of the nasal anti-CD3 in a ... Multiple Sclerosis: Cell-Catching Implant Helps Identify Successful Treatment in Mice Feb. 18, 2025 — A sponge-like implant in mice helped ...

SAVANNAH, Ga. (WTOC) - March is Multiple Sclerosis awareness month. It’s an autoimmune disease that impacts nearly a million people around the world. This month, our Jasmine Butler is bringing us ...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple ...

Washington: An American neurologist and an Italian epidemiologist whose work revolutionized the treatment of multiple sclerosis on Saturday won a prestigious Breakthrough Prize, the award ...

Researchers from the Netherlands Institute for Neuroscience (NIN) have discovered new potential therapeutic targets for multiple sclerosis (MS). While current treatments prevent further damage ...

More information: Repurposing Clinical MRI Archives for Multiple Sclerosis Research with a Flexible, Single-Contrast Approach: New Insights from Old Scans, Nature Communications (2025). DOI: 10. ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib ...

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed. A new artificial ...

Hauser's work on multiple sclerosis (MS) started more than 45 years ago, when he met a young patient named Andrea, "an extraordinarily talented young woman who was already an attorney" and working ...

The latest episode of The Wellness Conversation – an OhioHealth Podcast, delves into the complexities of Multiple Sclerosis (MS) through an insightful interview with Dr. Mysheika W. Roberts ...

More data are needed on its efficacy and safety in treating relapsing multiple sclerosis. In two phase 3, double-blind, double-dummy, event-driven trials (GEMINI 1 and GEMINI 2), participants with ...